CENEXI

The company declared its first-ever post-listing dividend of Rs 20 per equity share for FY24.

Indian generic injectables maker Gland Pharma reported fourth-quarter profit below estimates on Wednesday, as soaring employee expenses outweighed strong demand in its core markets.

Shares of Gland Pharma dropped 6% to Rs 1,745 on BSE as entities related to ex-promoter Dr Ravi Penmetsa sold 5.5% equity. Large block deals of 91 lakh shares worth Rs 1,600 crore reported.

Morgan Stanley maintained an Equal Weight rating on Crompton Greaves Consumer and an overweight rating on Bharat Forge. Jefferies recommended a hold rating on M&M and BofA Securities recommended a buy on Gland Pharma.

Meanwhile, the company's earnings before interest, taxes, depreciation and amortization (EBITDA) came in at Rs 320.5 crore, up from Rs 297 crore in the year-ago period.

A better pricing environment in the US, impending product launches, and prospects of superior profitability are also seen boosting the earnings of the company going ahead, analysts said.

From the Sensex pack, Power Grid, M&M, JSW Steel, Sun Pharma, Nestle and Relaince Industries closed in the red. The market breadth was skewed in the favour of the bulls. About 1,853 stocks gained, 1,751 declined, and 151 remained unchanged on the BS...

Global brokerage firm Jefferies upgraded Gland Pharma's stock to buy from underperform with an increased price target of Rs 1,640 from Rs 1,065 earlier. Bernstein also gave an outperform rating on Gland Pharma, saying that the Q1 numbers point towar...

The BSE Sensex was trading 22 points or 0.03% higher at 65,976. Nifty50 was trading at 19,604, up 7 points or 0.04% at around 9.23 am.

Gland Pharma's stock prices hit a 20% lower circuit on BSE after the firm reported a 72% YoY drop in net profit to Rs 79 crore in Q4FY23 due to a production shutdown at one of its facilities in Telangana and soft demand. The company had posted a net...

Gland Pharma on Thursday reported 72% year-on-year (YoY) drop in net profit to Rs 79 crores in Q4FY23 due to production shutdown at one of its facilities in Telangana and soft demand. The company reported net profit of Rs 285 crores in the same quar...

Gland Pharma, incorporated in the year 1978, is a Small Cap company (having a market cap of Rs 22233.18 Crore) operating in Pharmaceuticals sector.

From being the country’s biggest IPO, Paytm ended up being the biggest wealth destroyer over the past year. Amidst net losses, investors have increasingly shown discomfort over the complicated business model of the financial services company.

Buyout firms Advent International, Baring Private Equity Asia (now owned by EQT), Bain Capital, Blackstone, Carlyle and KKR are among those who have been approached to buy the Fosun-owned Gland Pharma, in what would be one of the largest pharma deal...

Offices and schools have opened, which creates an incremental demand for shoes and that benefits the shoe manufacturers, the brokerage said. After growing in metro cities, management has now shifted its focus to tier 2 & 3 cities where management se...

Cenexi, along with its subsidiaries, is engaged primarily in the business of Contract Development & Manufacturing Organisation (CDMO) of pharmaceutical products with expertise in sterile liquid and lyophilized fill finished drugs, including capabili...

Gland Pharma, incorporated in the year 1978, is a Small Cap company (having a market cap of Rs 30927.66 Crore) operating in Pharmaceuticals sector.

BNP Paribas Arbitrage offloaded over 18,00,164 lakh shares at an average price of Rs 405 apiece of IT major Wipro for Rs 72.9 crore through an open market transaction.